Heru develops autonomous AI-powered vision diagnostics and augmentation software that runs on commercially available AR/VR headsets to detect and correct vision defects in real time. The company’s core product is the Heru RE platform, registered with the U.S. FDA as a Class I exempt device, and designed to diagnose a wide range of eye diseases without large capital equipment or dedicated exam rooms. Heru’s software is compatible with off-the-shelf headsets including Microsoft and Magic Leap and the company collaborates with next‑generation AR headset developers. Heru holds 24 patents on vision augmentation and wearable diagnostics and exclusively licenses a full technology suite from Bascom Palmer Eye Institute. The company is developing vision augmentation features that use AI to customize correction for individual users and to support greater diagnostic care for eye care physicians. Financially, Heru has completed a seed round and an FDA registration and is advancing product development with new Series A financing. Heru is a Bascom Palmer Eye Institute spinout that has developed patented AI-powered vision diagnostics and augmentation software for commercial AR/VR head-mounted displays. The company’s cloud-based platform includes an autonomous diagnostic application for Visual Field Exams and is the only solution described in the release that can autonomously diagnose vision defects and customize individual vision augmentation. Heru completed a Class I listing with the U.S. FDA for its platform’s first diagnostic application and is conducting clinical trials aimed at FDA clearance for its wearable AI platform. The $2.7M seed round announced in June 2020 is intended to fund completion of those trials and subsequent commercialization efforts. Heru cites prevalence data (more than 50M U.S. patients; 450M worldwide) for conditions that cause visual field defects to justify its addressable need and scale. The company was founded in 2018, originated from the University of Miami/Bascom Palmer Eye Institute, and is led by Mohamed Abou Shousha, MD, with John T. Trefethen named Chief Marketing Officer.

Total raised

$33M

Funding rounds

2

Latest round

Series A

Latest activity

May 2021